Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704052 · ClinicalTrials.gov registry record · Early Phase 1
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 116
- Enrollment target
NCT02704052 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 116 participants.
The verdict
NCT02704052, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is the proximate cause of death in over 100,000 hospitalized patients per year. This project will critically examine the pharmacokinetics of prophylactic doses of enoxaparin in surgical patients, and will evaluate how alteration of enoxaparin dose magnitude and frequency affects peak and trough aFXa levels as well as risk for re-operative hematoma. If subtherapeutic aFXa levels are observed, the study will design, implement and test a clinical protocol to optimize post-operative aFXa levels. Although not an explicit Aim, this study will also provide important preliminary data on VTE rates in surgical patients with in range and out of range aFXa levels.
Interventions
- DRUG Real time enoxaparin dose adjustment
- DRUG Standard enoxaparin dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704052
The ClinicalTrials.gov registry entry for NCT02704052 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Real time enoxaparin dose adjustment is the first listed.
NCT02704052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02704052 about?
NCT02704052 is a clinical study titled "Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose". Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is the proximate cause of death in over 100,000 hospitalized patients per year. This project will critically examine the pharmacokinetics of prophylactic doses of enoxaparin in surgical patients, and will eva...
What is the current status of trial NCT02704052?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 116 participants. The study started on 2016-03. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02704052?
The interventions under investigation include: Real time enoxaparin dose adjustment (DRUG), Standard enoxaparin dose (DRUG).
Who is sponsoring clinical trial NCT02704052?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.